Back to top
more

Zoetis Inc. (ZTS)

(Real Time Quote from BATS)

$85.95 USD

85.95
1,505,920

+0.21 (0.25%)

Updated Jul 18, 2018 03:58 PM ET

Add to portfolio

3-Hold     3    

C Value | A Growth | F Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $3

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.71%
2 Buy 18.12%
3 Hold 9.91%
4 Sell 5.49%
5 Strong Sell 2.29%
S&P 500 9.79%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

CTLT vs. ZTS: Which Stock Is the Better Value Option?

CTLT vs. ZTS: Which Stock Is the Better Value Option?

CTLT  ZTS

Zacks Equity Research

Top Stock Reports for PayPal, ConocoPhillips & T-Mobile

Today's Research Daily features new research reports on 16 major stocks, including PayPal (PYPL), ConocoPhillips (COP) and T-Mobile (TMUS).

TMUS  COP  ZTS  ECL  PCAR  PYPL

Zacks Equity Research

Abaxis (ABAX) and Zoetis Merger Deal Crosses HRS Hurdle

With the adoption of Abaxis' (ABAX) point-of-care diagnostic instruments post acquisition, the combined entity's veterinary diagnostics category should grow faster than the animal health industry.

ABAX  GHDX  ZTS  ALGN

Zacks Equity Research

Zoetis (ZTS) Tides Over HSR Hurdle for Abaxis Acquisition

Zoetis' (ZTS) waiting period under the HSR Act ends. It is related to its proposed merger with Abaxis for a purchase consideration of roughly $2 billion in aggregate.

ABAX  GHDX  TARO  ZTS

Zacks Equity Research

CTLT vs. ZTS: Which Stock Should Value Investors Buy Now?

CTLT vs. ZTS: Which Stock Is the Better Value Option?

CTLT  ZTS

Zacks Equity Research

Why Is Zoetis (ZTS) Up 5.7% Since Its Last Earnings Report?

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ZTS

Zacks Equity Research

Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

AZN  PFE  LLY  NVS  JNJ  GSK  AMGN  ZTS  TEVA

Zacks Equity Research

Abaxis (ABAX) to be Acquired by Zoetis, Shares All-Time High

Post takeover of Abaxis' (ABAX) point-of-care diagnostic instruments, Zoetis expects the consolidated company's veterinary diagnostics category to speed up growth over the animal health industry.

VAR  ABAX  GHDX  ZTS

Zacks Equity Research

Company News For May 17, 2018

Companies In The News are: FOXA,IQV,ABAX,ZTS,TEVA,BRK.B

BRK.B  ABAX  ZTS  TEVA  FOXA  IQV

Zacks Equity Research

Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion

Zoetis (ZTS) inks a definitive deal to acquire Caifornia-based Abaxis, for $83 per share in cash or a total of $2 billion.

ABAX  LGND  ENTA  ZTS

Zacks Equity Research

Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View

Zoetis (ZTS) exceeds both earnings and sales expectations in the first quarter of 2018.

LGND  CATB  ZTS  PTGX

Zacks Equity Research

Zoetis (ZTS) Q1 Earnings & Revenues Surpass Estimates

Zoetis surpassed earnings and sales estimates in the first quarter of 2018.

ZTS

Zacks Equity Research

Zoetis (ZTS) Gears Up for Q1 Earnings: What's in Store?

Zoetis' (ZTS) top line in the first quarter is likely to be driven by continued demand for dermatology portfolio and product launches.

EBS  VNDA  ADVM  ZTS

Zacks Equity Research

Merck Gets European Committee Vote for Veterinary Product

Merck (MRK) is seeking approval of Bravecto Plus, a spot-on solution for cats. The drug is part of the company's Animal Health unit.

PFE  LLY  MRK  ZTS

Zacks Equity Research

Zoetis (ZTS) Up 7.8% Since Earnings Report: Can It Continue?

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ZTS

Zacks Equity Research

M&A, Innovation & New Drugs to Drive Pharma Stocks

The new tax law, which cuts the corporate tax rate from 35% to 21% and encourages companies to bring back cash held overseas at a one-time tax rate of 10%, is expected to spur merger activity.

SMMT  ZTS  GEMP  HZNP  INCY  CELG  GILD  REGN  AMPH  ABBV  MRK  NVS  NVO  PFE  BMY  AZN  SNY

Madeleine Johnson

Bear of the Day: Endo International (ENDP)

Litigation has hit this opioid drug maker hard. Is there any chance for a rebound?

ZTS  ENDP

Mark Vickery

Top Stock Reports for Texas Instruments, Statoil & Comcast

Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments (TXN), Statoil (STO) and Comcast (CMCSA).

LRCX  TXN  EQNR  ZTS  CMCSA  HPQ

Zacks Equity Research

Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View

Zoetis' (ZTS) results exceed both earnings and sales expectations in the fourth quarter of 2017, making it the first animal health company to deliver more than $5 billion in revenues.

XOMA  EXEL  ENTA  ZTS

Zacks Equity Research

Zoetis (ZTS) Q4 Earnings & Revenues Surpass Estimates

Zoetis surpassed earnings and sales estimates in the fourth quarter of 2017.

ZTS

Zacks Equity Research

Zoetis (ZTS) Warming Up to Q4 Earnings: What's in Store?

Zoetis (ZTS) is working on returning value to shareholders in the form of share buybacks and dividends.

ALKS  EXEL  ANTH  ZTS

Zacks Equity Research

Teva Completes Sale of Women's Health Segment for $703M

Teva Pharmaceutical (TEVA) sells woman health specialty products for cash consideration of $703 million.

AGN  ZTS  TEVA  MYL

David Bartosiak

5 Stocks You Can't Afford to Ignore

These five stocks are breaking out to new highs as earnings estimates continue to come in to the upside.

UNP  MTZ  ZTS  TGT  KSS

Zacks Equity Research

7 GARP Stocks That Should Feature in Your Portfolio

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

MSCI  TPX  ITW  ZTS  CRI  DRI  TTC

Zacks Equity Research

Can These 4 Large-Cap Drug Stocks Deliver an Encore in '18?

We present four large cap drug companies, which are expected to repeat their last year's industry beating performance in 2018.

NVO  JNJ  ABBV  AMGN  ZTS

Mark Vickery

Top Stock Reports for Apple, Facebook & MetLife

Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Facebook (FB) and MetLife (MET).

ZTS  CI  MET  AAPL  FB  LUV

Zacks Equity Research

Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND

The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.

PFE  AGN  LGND  PBYI  ZTS  MYL  XON

Zacks Equity Research

Key Predictions for Q3 Earnings Reports of MYL, HZNP & KERX

The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if generic maker Mylan and other small companies follow suit.

PFE  AGN  HZNP  KERX  ZTS  MYL

Zacks Equity Research

Zoetis (ZTS) Beats on Q3 Earnings & Sales, Ups 2017 View

Zoetis (ZTS) reported impressive third-quarter results beating estimates on both counts. Revenues were driven by strong demand for companion animal products worldwide.

MYGN  EXEL  AGEN  ZTS

Zacks Equity Research

Zoetis (ZTS) Q3 Earnings & Sales Beat Estimate; 2017 View Up

Zoetis (ZTS) announced third quarter results with earnings and sales both beating estimates.

ZTS